A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emraclidine Moves Through the Body in Adult Participants With Schizophrenia
Phase 2
258
about 2.6 years
18–65
7 sites in AR, CA, MD +2
About this study
Researchers are testing a treatment called emraclidine for people with schizophrenia. The trial will look at any side effects that may occur, how well the treatment works to reduce symptoms of schizophrenia, and how the drug moves through your body. Participants will receive either oral emraclidine or placebo for up to 42 days.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Emraclidine
- 2.Take Placebo
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Primary: Number of Participants with Adverse Events (AEs), Part A Only- Accumulation ratio for Cmax (RacCmax) of Emraclidine, Part A Only- Terminal Phase Elimination Half-Life (t1/2) of Emraclidine, Part A Only-Apparent Clearance of Drug from Plasma (CL/F) of Emraclidine, Part A Only-Maximum Observed Plasma Concentration (Cmax) of Emraclidine, Part A Only-Maximum Observed Plasma Concentration (Cmax) of Metabolite (CV-0000364), Part A Only-Time to Cmax (Tmax) of Emraclidine, Part A Only-Time to Cmax (Tmax) of Metabolite (CV-0000364)
Secondary: Part B Only-Change from Baseline in Positive and Negative Syndrome Scale (PANSS) total score, Part B Only-Change from Baseline in in Clinical Global Impression of Severity (CGIS) score
Psychiatry / Mental Health